Literature DB >> 22594992

Interleukin-4 polymorphisms and response to combination therapy in Egyptian chronic hepatitis C patients.

Sally M Shalaby1, Mohamed I Radwan, Shymaa Abdelazim, Abeer M Nafee.   

Abstract

In hepatitis C infection, the production of inappropriate cytokines levels may contribute to viral persistence and may affect the response to antiviral therapy. We investigate the effect of IL4 C-590T and C-33T polymorphisms on the response to combination therapy with interferon and ribavirin in chronic HCV patients. These single nucleotide polymorphisms were determined by PCR-RFLP in 235 responder and 210 non-responder to combination therapy. The IL4-590 T/T and -33 T/T genotypes were associated with resistance to the therapy (p<0.001, p=0.001 respectively). Haplotypes T(-590) T(-33) and T(-590) C(-33) were associated with a higher risk in non-responder patients than the responders (p<0.001 for each) while frequency of haplotype C(-590) C(-33) (with all wild alleles) was significantly higher in responders as compared to non-responders (p<0.001). These results suggest that inheritance of the IL4 polymorphisms may be associated with resistance to combined antiviral therapy in Egyptian HCV patients.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22594992     DOI: 10.1016/j.cellimm.2012.04.009

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Cytokines Interleukin 4 (IL-4) and Interleukin 10 (IL-10) Gene Polymorphisms as Potential Host Susceptibility Factors in Virus-Induced Encephalitis.

Authors:  Ying Yu; Ying Chen; Feng-Ling Wang; Jing Sun; Hai-Jun Li; Jia-Ming Liu
Journal:  Med Sci Monit       Date:  2017-09-22

2.  Polymorphisms of α1-antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection.

Authors:  T Motawi; O G Shaker; R M Hussein; M Houssen
Journal:  Balkan J Med Genet       Date:  2017-03-09       Impact factor: 0.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.